Cargando…

Characterization of a Potent and Orally Bioavailable Lys-Covalent Inhibitor of Apoptosis Protein (IAP) Antagonist

[Image: see text] We have recently reported on the use of aryl-fluorosulfates in designing water- and plasma-stable agents that covalently target Lys, Tyr, or His residues in the BIR3 domain of the inhibitor of the apoptosis protein (IAP) family. Here, we report further structural, cellular, and pha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Udompholkul, Parima, Garza-Granados, Ana, Alboreggia, Giulia, Baggio, Carlo, McGuire, Jack, Pegan, Scott D., Pellecchia, Maurizio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2023
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10291551/ https://www.ncbi.nlm.nih.gov/pubmed/37262387 http://dx.doi.org/10.1021/acs.jmedchem.3c00467

Ejemplares similares

Mixture-Based Screening of Focused Combinatorial Libraries by NMR: Application to the Antiapoptotic Protein hMcl-1
por: Alboreggia, Giulia, et al.
Publicado: (2023)

Targefrin: A Potent Agent Targeting the Ligand Binding Domain of EphA2
por: Baggio, Carlo, et al.
Publicado: (2022)

Therapeutic Targeting of Pancreatic Cancer via EphA2 Dimeric Agonistic Agents
por: Salem, Ahmed F., et al.
Publicado: (2020)

Effective Tumor Targeting by EphA2-Agonist-Biotin-Streptavidin Conjugates
por: Udompholkul, Parima, et al.
Publicado: (2021)

Reduction of Circulating Cancer Cells and Metastases in Breast-Cancer Models by a Potent EphA2-Agonistic Peptide–Drug Conjugate
por: Salem, Ahmed F., et al.
Publicado: (2018)

IAP antagonist GDC-0917 is more potent than Debio1143 in promoting cell death, c-IAP1 degradation and tumor growth inhibition
por: Alicke, Bruno, et al.
Publicado: (2022)

Bivalent IAP antagonists, but not monovalent IAP antagonists, inhibit TNF-mediated NF-κB signaling by degrading TRAF2-associated cIAP1 in cancer cells
por: Mitsuuchi, Y, et al.
Publicado: (2017)

Triggering necroptosis in cisplatin and IAP antagonist-resistant ovarian carcinoma
por: McCabe, K E, et al.
Publicado: (2014)

Lipopolysaccharide sensitizes the therapeutic response of breast cancer to IAP antagonist
por: Liu, Xin, et al.
Publicado: (2022)

The expanding role of IAP antagonists for the treatment of head and neck cancer
por: Kansal, Vikash, et al.
Publicado: (2023)

Bivalent IAP antagonists inhibit TRAF2-bound cIAPs and limit TNF-mediated NF-κB signaling
por: Condon, Stephen M
Publicado: (2016)

Drosophila IAP antagonists form multimeric complexes to promote cell death
por: Sandu, Cristinel, et al.
Publicado: (2010)

IAP antagonists sensitize murine osteosarcoma cells to killing by TNFα
por: Shekhar, Tanmay M., et al.
Publicado: (2016)

Clinical Positioning of the IAP Antagonist Tolinapant (ASTX660) in Colorectal Cancer
por: Crawford, Nyree, et al.
Publicado: (2021)

Pellino-1 confers chemoresistance in lung cancer cells by upregulating cIAP2 through Lys63-mediated polyubiquitination
por: Jeon, Yoon Kyung, et al.
Publicado: (2016)

The IAP antagonist birinapant potentiates bortezomib anti-myeloma activity in vitro and in vivo
por: Zhou, Liang, et al.
Publicado: (2019)

IAP Workshop
Publicado: (1996)

Intragenic antimicrobial peptides (IAPs) from human proteins with potent antimicrobial and anti-inflammatory activity
por: Brand, Guilherme D., et al.
Publicado: (2019)

Effects of Physiological and Synthetic IAP Antagonism on c-IAP-Dependent Signaling
por: Kocab, Andrew J., et al.
Publicado: (2015)

Taking aim with IAP antagonists at triple-negative breast cancer: a moving target no more?
por: LaCasse, Eric C.
Publicado: (2020)

The non‐peptidomimetic IAP antagonist ASTX660 sensitizes colorectal cancer cells for extrinsic apoptosis
por: Knoll, Gertrud, et al.
Publicado: (2021)

Structural insights into non-covalent ubiquitin activation of the cIAP1-UbcH5B∼ubiquitin complex
por: Patel, Amrita, et al.
Publicado: (2019)

IAP textbook of vaccines
por: Kabra, S. K.
Publicado: (2016)

IAPS Presidential Address
por: Ramadwar, Ravindra
Publicado: (2022)

IAP-IAP Complexes Required for Apoptosis Resistance of C. trachomatis–Infected Cells
por: Rajalingam, Krishnaraj, et al.
Publicado: (2006)

Identification of mTOR as a primary resistance factor of the IAP antagonist AT406 in hepatocellular carcinoma cells
por: Zhen, Mao-Chuan, et al.
Publicado: (2016)

PTEN deficiency promotes macrophage infiltration and hypersensitivity of prostate cancer to IAP antagonist/radiation combination therapy
por: Armstrong, Chris W.D., et al.
Publicado: (2016)

Structure-based design, synthesis, and evaluation of the biological activity of novel phosphoroorganic small molecule IAP antagonists
por: Łupicka-Słowik, Agnieszka, et al.
Publicado: (2020)

The IAP Antagonist SM-164 Eliminates Triple-Negative Breast Cancer Metastasis to Bone and Lung in Mice
por: Lei, Wei, et al.
Publicado: (2020)

The IAP antagonist birinapant enhances chimeric antigen receptor T cell therapy for glioblastoma by overcoming antigen heterogeneity
por: Song, Edward Z., et al.
Publicado: (2022)

IAP Display: A Simple Method to Identify Mouse Strain Specific IAP Insertions
por: Ray, Akshay, et al.
Publicado: (2010)

c-IAP1 and c-IAP2 Redundancy Differs between T and B Cells
por: Giardino Torchia, Maria Letizia, et al.
Publicado: (2013)

A novel small-molecule IAP antagonist, AZD5582, draws Mcl-1 down-regulation for induction of apoptosis through targeting of cIAP1 and XIAP in human pancreatic cancer
por: Moon, Jai-Hee, et al.
Publicado: (2015)

Engineered (Lys)(6)-Tagged Recombinant Sulfide-Reactive Hemoglobin I for Covalent Immobilization at Multiwalled Carbon Nanotubes
por: Díaz-Ayala, Ramonita, et al.
Publicado: (2017)

HSA-Lys-161 covalent bound fluorescent dye for in vivo blood drug dynamic imaging and tumor mapping
por: Yue, Yongkang, et al.
Publicado: (2021)

RANKL enhances the effect of an antagonist of inhibitor of apoptosis proteins (cIAPs) in RANK-positive breast cancer cells
por: Casimiro, S., et al.
Publicado: (2013)

Combination of IAP Antagonists and TNF-α-Armed Oncolytic Viruses Induce Tumor Vascular Shutdown and Tumor Regression
por: Beug, Shawn T., et al.
Publicado: (2018)

Development of Peptidomimetics Targeting IAPs
por: Sharma, Sushil K., et al.
Publicado: (2006)

Development of rebunching cavities at IAP
por: Welsch, C P, et al.
Publicado: (2000)

IAPS Textbook of Pediatric Surgery
por: Jacobsen, Anette
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6eiam7m4td3c37pqrh59l4h099